GGGuillaume Gantois

Guillaume Gantois

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guillaume Gantois has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • André Vincentelli

    Heart and Lung Institute, Cardiac Surgery Department, CHU Lille, F-59000

    1 shared publication
  • Anne-Laure Piton

    Department of Internal Medicine and Clinical immunology, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, Lille, France

    1 shared publication
  • Antoine Lamer

    Certified Research Unit 2694 - METRICS: Assessment of Health Technologies and Medical Practices, University of Lille, Lille University Hospital, Lille, France

    1 shared publication
  • Arthur Durand

    Published online 16 January 2019

    1 shared publication
  • Ava Diarra

    Department of Infectious Diseases and Tropical Medicine, AP-HP, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne and Hôpital Jean Verdier , Bobigny

    1 shared publication
  • Basile Verdier

    Department of Cardiology, CHU Lille, Lille, France

    1 shared publication

Latest Publications

  • Open Access

    Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab

    by Ava Diarra, Guillaume Gantois, Mouna Lazrek, Basile Verdier, Vincent Elsermans, Hélène Zephir, Benjamin Longère, Xristos Gkizas, Céline Goeminne, Gilles Lemesle, et al.

    Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.


  • Central venous-to-arterial PCO2 difference, arteriovenous oxygen content and outcome after adult cardiac surgery with cardiopulmonary bypass

    by Mouhamed D. Moussa, Arthur Durand, Guillaume Leroy, Liu Vincent, Antoine Lamer, Guillaume Gantois, Olivier Joulin, Slimane Ait-Ouarab, Delphine Deblauwe, Brandt Caroline, et al.

    Rapid identification and treatment of tissue hypoxia reaching anaerobiosis (dysoxia) may reduce organ failure and the occurrence of major postoperative complications (MPC) after cardiac surgery. The predictive ability of PCO2-based dysoxia biomarkers, central venous-to-arterial PCO2 difference (ΔPCO2) and ΔPCO2 to arteriovenous oxygen content difference ratio, is poorly studied in this setting. We evaluated the ability of PCO2-based tissue dysoxia biomarkers, blood lactate concentration and central venous oxygen saturation measured 2 h after admission to the ICU as predictors of MPC. A prospective, observational cohort study. Single-centre, academic hospital cardiovascular ICU. We included adult patients undergoing cardiac surgery with cardiopulmonary bypass and measured dysoxia biomarkers at ICU admission, and after 2, 6 and 24 h. The primary endpoint was MPC, a composite of cardiac and noncardiac MPC evaluated in the 48 h following surgery. After univariate analysis of MPC covariates including dysoxia biomarkers measured at 2 h, multivariate logistic regression analyses were performed to identify the association of these biomarkers with MPC for confounders. Areas under the receiver operating characteristic curves were determined for biomarkers which remained independently associated with MPC. MPC occurred in 56.5% of the 308 patients analysed. ΔPCO2, blood lactate concentration and central venous oxygen saturation measured at 2 h, but not ΔPCO2 to arteriovenous oxygen content difference ratio, were significantly associated with MPC. However, only ΔPCO2 was independently associated with MPC after multivariate analysis. The areas under the receiver operating characteristic curves of ΔPCO2 measured at 2 h for MPC prediction was 0.64 (95% CI 0.57 to 0.70, P < 0.001). After cardiac surgery with cardiopulmonary bypass, ΔPCO2 measured 2 h after ICU admission was the only dysoxia biomarker independently associated with MPC, but with limited performance. ClinicalTrials.gov, NCT03107572.